Loading...

PASG PASSAGE BIO INC US FDA Inspections 8-K Filing

PSSG

PSG

PASSAGE BIO INC

(PASG)

2024 8-K

Show Summary

Show Summary

Management Changes

Financial Statements

Financial Results

Nasdaq Compliance

Restructuring Plan

Financial Results

Scientific Presentation

Clinical Trial Update

Director Appointment

Sublease Agreement

Financial Results and Corpo...

Sublicense Agreements

FDA Feedback on PBFT02 for ...

Annual Meeting of Stockholders

Earnings Reports

Financial Results and CFO A...

Compliance with Nasdaq List...

Regulation FD Disclosure

Settlement Agreement

PBFT02 Program Updates

Earnings Release

Delisting Notice

Earnings Report & Conferenc...

Departure and Appointment o...

Management Changes

Annual Meeting of Stockholders

Financial Results and Corpo...

Agreement Amendments with C...

FDIC Receiver of Silicon Va...

Earnings Reports

Presentation and Press Release

Financial Update

External Links:

Passage Bio, Inc. announced positive feedback from the FDA on its proposal to evaluate PBFT02 for treating frontotemporal dementia (FTD) patients with mutations in the C9orf72 gene.

AI Assistant

PASSAGE BIO INC

2024

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.